• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pulmatrix raises $3m in offering

November 30, 2018 By Sarah Faulkner

PulmatrixPulmatrix (NSDQ:PULM) said this week that it inked a deal with an institutional investor to sell 9,375,000 shares of common stock at
32¢ apiece.

The Lexington, Mass.-based company expects to reel in $3 million in total gross proceeds from the offering.

Pulmatrix also agreed to issue unregistered warrants to the same investor in a private placement to buy up to one share of common stock for each share or common stock bought with an exercise price of 39¢ per share. The warrants will be exercisable six months after the date they were issued, the company said, and will expire five and half years later.

Pulmatrix expects the offering to close on Dec. 3.

Earlier this month, Pulmatrix touted the final results of its first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.

According to the results of the study, Pulmazole was well tolerated in normaly healthy subjects at doses up to 35 mg over 14 days of dosing. Single doses of Pulmazole at 20 mg were safe and well tolerated in participants with asthma, the company noted.

Pulmatrix also reported that patients experienced sustained low-level systemic exposure after single and multiple doses over 24 hours following drug administration. The most common adverse event reported during the study was a mild cough during dosing.

The company expects to launch a Phase II trial in Q4 this year to test the drug as a therapy for allergic bronchopulmonary aspergillosis in people with asthma.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS